Atterocor Appoints Jeffery M. Brinza as Senior Vice President, Administration and General Counsel

ANN ARBOR, Mich.--(BUSINESS WIRE)--Atterocor, Inc., a company developing novel therapies for rare endocrine disorders, today announced the appointment of Jeffery M. Brinza as Senior Vice President, Administration and General Counsel. Mr. Brinza will serve as a member of the Atterocor Senior Management Team and will provide the company's legal counsel and oversee all administrative functions. Mr. Brinza joins Atterocor from RGIS, LLC, a Blackstone portfolio company.

"I look forward to working with this team to execute on our strategy and bring novel therapies to patients with limited treatment options."
"Jeff brings extensive experience within pharmaceutical and life science companies and is an excellent addition to the team to assist our ongoing development efforts," said Julia C. Owens, Ph.D., President and Chief Executive Officer of Atterocor. "We welcome Jeff to the team at a crucial stage of Atterocor's growth and look forward to his contributions as we continue development of therapies for patients with high unmet medical need."

Prior to Atterocor, Mr. Brinza was General Counsel, Secretary and Chief Compliance Officer for RGIS, LLC, a Blackstone portfolio company, where he led the legal and human resources departments. Previously, he served as General Counsel and Secretary at QuatRx Pharmaceuticals, where he managed the legal, IT and human resources functions, negotiated numerous product licensing agreements, and worked on several financing transactions. His career has also included acting as outside General Counsel for several startup companies from the University of Michigan, and working for the international legal group of Abbott Laboratories. Earlier in his career, Mr. Brinza was Assistant General Counsel for the Parke-Davis Pharmaceutical Research Division of Warner-Lambert.

"I am honored to join the talented leadership team at Atterocor at such an exciting and transformative time in the company's development," said Mr. Brinza. "I look forward to working with this team to execute on our strategy and bring novel therapies to patients with limited treatment options."

Mr. Brinza is a member of the Michigan Bar Association, American Bar Association, and Association of Corporate Counsel. Currently, he is a member of the Board of Directors of ENT Biotech Solutions, a medical device startup. Mr. Brinza holds a Juris Doctorate degree from the University of Michigan Law School, and a B.A. in computer and communications sciences and economics from the University of Michigan.

About Atterocor, Inc.

Atterocor is focused on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. Our product candidates seek to improve the quality of life for patients with orphan and specialty diseases with limited or no approved treatment options.

Contacts

MacDougall Biomedical Communications
Blair McCarthy Atkinson
Main: +1-781-235-3060
Direct: +1-812-454-6257
[email protected]

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.